Aptamers as theranostic agents: modifications, serum stability and functionalisation - Wikidata - wikimedia - TriplyDB

Aptamers as theranostic agents: modifications, serum stability and functionalisation

Aptamers as theranostic agents: modifications, serum stability and functionalisation

http://www.wikidata.org/entity/Q37383122

about

Targeting Th17 Cells with Small Molecules and Small Interference RNA Multivalent Aptamers: Versatile Tools for Diagnostic and Therapeutic Applications Therapeutic aptamers: developmental potential as anticancer drugs Ex Vivo and In Vivo Imaging and Biodistribution of Aptamers Targeting the Human Matrix MetalloProtease-9 in Melanomas An 'activatable' aptamer-based fluorescence probe for the detection of HepG2 cells.Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine Molecular Recognition of Human Liver Cancer Cells Using DNA Aptamers Generated via Cell-SELEX.RAID3--An interleukin-6 receptor-binding aptamer with post-selective modification-resistant affinity Superior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid Tumors Post-SELEX optimization of aptamers.High throughput sequencing analysis of RNA libraries reveals the influences of initial library and PCR methods on SELEX efficiency.Rapid Complexation of Aptamers by Their Specific Antidotes.Predicting the Uncertain Future of Aptamer-Based Diagnostics and Therapeutics.Status and Prospects of Aptamers as Drug Components.Trends in the Design and Development of Specific Aptamers Against Peptides and Proteins.Aptamers as the Agent in Decontamination Assays (Apta-Decontamination Assays): From the Environment to the Potential Application In Vivo.EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs.Aptamer: A potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma.Effect of Chemical Modifications on Aptamer Stability in Serum.Molecular modeling and SPRi investigations of interleukin 6 (IL6) protein and DNA aptamers.

P2860

Q26770523-E1EEF5E2-D9FF-4DDC-878A-4E9839540243 Q28073119-E9E57573-EF08-4269-9CFC-495821A1BFBD Q28085157-F88B414E-3C9B-49E2-A6D0-08DB32157AA9 Q28550308-1FC0139D-0337-4A94-AAF8-05DEAEBEA1C4 Q33674521-647EAE6E-3C5E-4443-9DBB-8918BA684F6E Q33832781-7DF33A1E-CE70-471E-BCE0-9D3D9D79B78A Q34698624-B29E4AEE-BCBF-4252-A98A-745A8AF7ECE5 Q35621766-6AC44E41-37EC-4C4F-B5AC-7638F8490002 Q35780423-7F668DEC-3D6B-41EF-A41F-5019AFD16439 Q35868868-C9ED452E-A7BA-48F5-A9B2-D07E5E612550 Q36016288-9E418B3F-4A1F-4778-9234-79DD5596A585 Q36139325-65D6293D-EEAD-4D00-88F4-4BA6B98134C2 Q38287977-AC73AC9C-6EA6-4E90-93DE-61E70136DE02 Q38443249-C2330604-4321-4384-9927-C70B725697AC Q38488502-78320A00-3007-42D1-BD9D-C49E592F6787 Q38777639-4D6209ED-F48B-4C21-8DE9-C1F167ECED99 Q47150038-4C5385CC-35D3-4606-94F0-62AF02750E93 Q47735319-CC982EE6-C16B-438F-98FA-FB8557041849 Q49163466-B29BE9F8-E07C-4ABE-BFBF-CE0AE3895E94 Q49850199-7D2A76E0-81B3-445A-B644-1EBEBF58056F Q50954695-808FAEFE-0D92-4CFD-BCB6-E3F37EADB187

P2860

Aptamers as theranostic agents: modifications, serum stability and functionalisation

http://www.wikidata.org/entity/Q37383122

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Aptamers as theranostic agents: modifications, serum stability and functionalisation

@en

Aptamers as theranostic agents: modifications, serum stability and functionalisation.

@nl

type

label

Aptamers as theranostic agents: modifications, serum stability and functionalisation

@en

Aptamers as theranostic agents: modifications, serum stability and functionalisation.

@nl

prefLabel

Aptamers as theranostic agents: modifications, serum stability and functionalisation

@en

Aptamers as theranostic agents: modifications, serum stability and functionalisation.

@nl

P1433

Q37383122-EF9726CE-8F0F-4922-96E5-49ECC79C1094

P1476

Q37383122-492E0A46-B1B2-4220-9542-3DB5387F6043

P2093

Q37383122-17B6A3F8-D4A1-4863-8864-391D5AA85649

Q37383122-27F55DF4-D5B7-42DD-A70F-268DEB6AE513

Q37383122-454FFC75-5732-496A-886C-8A4ED5E39839

Q37383122-4E764FCC-0E71-4400-94F4-3D3082F6CFF4

Q37383122-56C8CF20-4E88-4179-BAAE-860730097DB0

Q37383122-5D023F2A-34F3-478B-ABDE-E89F0BFF5BF1

Q37383122-66169E41-5EE2-4333-ADD4-5455BC05EAAD

Q37383122-CD1FDE7B-C537-423A-BCF8-DA961CCC3D1D

Q37383122-D6D878D1-33F8-421A-9405-10FCFA68FA47

Q37383122-E0118014-C31D-49B8-8DDB-C7FBD456C046

P275

Q37383122-6AA721D2-2E53-4481-BAFA-2ABD0EA13AA8

P2860

Q37383122-04E1C248-7F68-4BF4-BDAC-78B119574880

Q37383122-0B88EA1B-1E44-429E-9426-EA61BE8BD6D4

Q37383122-0BCD6E3F-F322-4E66-BBC5-29C9DBA42F5C

Q37383122-10F04D5C-EDE5-462E-A52D-665C42AE7B1B

Q37383122-126C1D15-A6C9-4E57-A36B-7671F73AE24A

Q37383122-12DFF7E7-48FC-4E6B-B805-77419E282587

Q37383122-15E4E3CA-42B0-4BC1-9753-677B01C97975

Q37383122-19763D04-486D-458F-82A5-AB7A15EFEF02

Q37383122-1E01057E-E2B2-4B90-B9EB-1D8B40D739BD

Q37383122-1E94F6FB-42C4-4CEF-92E9-518B1BE190BD

P304

Q37383122-24F11959-A502-48B3-9B39-A94A866EBC5A

P31

Q37383122-0F83055D-696C-4B6B-AB48-1B1DF6BD3E30

Q37383122-D0B85051-E442-4512-8F8F-7304FE38628E

P356

Q37383122-5B65BDBF-6A80-4DD4-BFB1-7BA1EF6337BC

P407

Q37383122-777809B7-5813-438E-B781-9033E63A7087

P433

Q37383122-29A90191-D8E0-4838-9593-83EF40800923

P478

Q37383122-99879964-35A1-4462-B370-8C7224EFC8E2

P50

Q37383122-6687E513-94EE-4F20-BB63-7D986AD00CB7

Q37383122-72B7E797-D9AF-4D0D-B486-9DEA11FFAE20

Q37383122-B44F4286-8B1B-48B3-BE8D-F946920340D2

P577

Q37383122-05E9CFE7-0C76-4909-B1DB-B15A27130927

P5875

Q37383122-F3A7B5B8-E65C-4AC5-8686-EB95FC8EC78D

P698

Q37383122-E2A32675-915F-4F05-8ACE-02E686B66FEE

P921

Q37383122-2F14F87B-32C3-430A-A08B-D7F42083B42C

Q37383122-60A7F5A3-982B-4F42-8266-21FC621FFBC0

Q37383122-D126492C-AF23-4968-B1B4-6DFD3FB5A88F

P932

Q37383122-145CC7E2-D852-4FEF-936D-6FF1E2FD7405

P356

P1433

P1476

Aptamers as theranostic agents: modifications, serum stability and functionalisation

@en

P2093

ChunGuang Li

http://www.w3.org/2001/XMLSchema#string

Dongxi Xiang

http://www.w3.org/2001/XMLSchema#string

Hadi Al Shamaileh

http://www.w3.org/2001/XMLSchema#string

Liang Qiao

http://www.w3.org/2001/XMLSchema#string

Lingxue Kong

http://www.w3.org/2001/XMLSchema#string

Michael O'Connor

http://www.w3.org/2001/XMLSchema#string

Ming Wei

http://www.w3.org/2001/XMLSchema#string

Sarah Shigdar

http://www.w3.org/2001/XMLSchema#string

Shu-Feng Zhou

http://www.w3.org/2001/XMLSchema#string

Wei Duan

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Quantum dots for live cells, in vivo imaging, and diagnostics

New NTP analogs: the synthesis of 4'-thioUTP and 4'-thioCTP and their utility for SELEX

Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase

Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets

Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase

In vitro selection of RNA molecules that bind specific ligands

Vienna RNA secondary structure server

Efficient reverse transcription using locked nucleic acid nucleotides towards the evolution of nuclease resistant RNA aptamers

Aptamer-based multiplexed proteomic technology for biomarker discovery

In vivo cancer targeting and imaging with semiconductor quantum dots

P304

13624-13637

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/S131013624

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Santanu Bhattacharya

Joanna Macdonald

P577

2013-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258038771

http://www.w3.org/2001/XMLSchema#string

P698

24152925

http://www.w3.org/2001/XMLSchema#string

P921

biomedical investigative technique

P932

3859083

http://www.w3.org/2001/XMLSchema#string